Ryan Fuhrmann

Ryan Fuhrmann

Ryan C. Fuhrmann, CFA, has a background in portfolio management, overseeing assets for high-net-worth individuals and covering a broad array of industries from a generalist perspective. An active student of investing, he is also committed to communicating his ideas as an investment writer and learning from the financial community. His Twitter handle is @rationalanalyst.

Recent Articles

3 Beaten-Down Generic Drugmakers to Buy

Generic drugmakers Mylan (MYL), Teva (TEVA) and Novartis (NOV) took a hit from DOJ subpoenas on speculation of price-fixing in the industry.

Facebook Inc (FB) Is a Better Bet Than Alphabet Inc (GOOGL)

Facebook (FB) might look expensive in a bubble, but given the ludicrous growth expectations for this blue chip, Facebook stock is a value.

3 Beaten-Down Biotech Stocks to Buy for Huge Gains

The following are three Biotech stocks to buy because of their long-term potential, which surpasses the recent onslaught of negative press and concern over higher drug prices.

3 Beaten-Down Healthcare Stocks to Buy

Allergan (AGN), Zimmer Biomet (ZBH) and McKesson (MCK) are three bona fide leaders in their respective healthcare industries.

3 Blue-Chip Stocks With Hidden Benefits

Returns come in many forms. These three blue-chip stocks offer some of the best benefits to investors that purchase their shares.

Nothing Can Stop Merck & Co., Inc. (MRK) Stock Now

MRK stock will likely continue its rise. This is supported by Merck & Co.'s momentum and first-place position in the appealing IO industry.

Wells Fargo & Co (WFC) Nomads Should Follow Buffett’s Lead

Wells Fargo's current predicament is unfortunate and completely its own doing, but it still has a solid overall reputation and among the best financial profiles in the banking industry.

Can Nvidia Corporation (NVDA) Stand Tall Amid New Competition?

Nvidia (NVDA) is moving into exciting growth markets, but investors are at risk because these markets are unproven and highly competitive.

GoPro Inc (GPRO) Hopeful About Karma’s Hype

Despite falling sales and profits, GoPro could be at an inflection point. Still, wait and see some hard numbers in GPRO stock before buying.

5 Water Stocks With Untapped Potential

The global water industry reports $700 billion in annual sales, or as much as the pharmaceutical industry. Here's how to invest.